Home

James F III Oliviero

CIK 1434718 · CEO, President and Director · last filed 2026-06-12

James F III Oliviero is a CEO, President and Director who has filed 67 SEC Form 4 insider transactions across 3 companies since 2008. The most recent filing, for NVCT, was dated Jun 12, 2026. Across all open-market trades the lifetime net is −$15.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.43M

Companies

3

Total Filings

67

Lifetime Open-Market Net

-$15.03M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NVCT Director 122,828 $19.82 $2.43M $0 5 2026-06-12
Checkpoint Therapeutics, Inc. (CKPT) Delisted CEO, President and Director 0 $4.26 $0 -$4.34M 22 2025-05-30
KERYX BIOPHARMACEUTICALS INC (KERX) Delisted Chief Financial Officer 209,406 — — -$10.69M 39 2015-07-08

Recent Filings

67 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-12 NVCT Grant (A) +35,000 $0 EDGAR
2025-06-12 NVCT Grant (A) +30,000 $0 EDGAR
2025-05-30 Checkpoint Therapeutics, Inc. (CKPT) Delisted U −3,759,929 $0 EDGAR
2025-04-03 Checkpoint Therapeutics, Inc. (CKPT) Delisted Sell (S) −15,090 -$61.0K EDGAR
2025-02-11 Checkpoint Therapeutics, Inc. (CKPT) Delisted Sell (S) −19,564 -$64.0K EDGAR
2025-01-31 Checkpoint Therapeutics, Inc. (CKPT) Delisted Grant (A) +1,500,000 $0 EDGAR
2024-12-20 Checkpoint Therapeutics, Inc. (CKPT) Delisted Mixed −1,722,397 -$3.07M EDGAR
2024-12-17 Checkpoint Therapeutics, Inc. (CKPT) Delisted Grant (A) +2,077,700 $0 EDGAR
2024-06-28 Checkpoint Therapeutics, Inc. (CKPT) Delisted Mixed −62,500 -$50.5K EDGAR
2024-06-13 NVCT Grant (A) +30,000 $0 EDGAR
Showing 1–10 of 67
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.